<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161483</url>
  </required_header>
  <id_info>
    <org_study_id>CC-220-SLE-002</org_study_id>
    <secondary_id>U1111-1195-7804</secondary_id>
    <nct_id>NCT03161483</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study
      to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in
      adult subjects with active systemic lupus erythematosus.

      Approximately 280 subjects with a documented diagnosis of SLE will be randomized 2:2:1:2 to
      receive CC-220 (0.45 mg QD, 0.3 mg QD or 0.15 mg QD) or identically appearing placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of four phases:

        -  4-week Screening Phase

        -  24-week placebo-controlled phase Subjects will receive either 0.45 mg QD, 0.3 mg QD,
           0.15 mg QD or placebo for the first 24 weeks of treatment.

        -  28-week active treatment phase At Week 24, all subjects on placebo will be re-randomized
           to active treatment.

        -  4-week observational follow-up All subjects who complete 52 weeks of treatment or
           discontinue the study early will enter a post-treatment observation follow-up phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">May 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve SRI(4) response- Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SRI(4) is a composite endpoint, defined by the following criteria:
Reduction from baseline of ≥ 4 points in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score and
No new one or more British Isles Lupus Assessment Group (BILAG) A or new 2 or more BILAG B items compared to baseline using BILAG 2004 Index and
No worsening from baseline defined by an increase of &lt; 0.30 points from baseline on a Physician's Global Assessment (PGA) visual analog scale (VAS) from 0-3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve SRI(4) response - Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI(4) is a composite endpoint, defined by the following criteria:
Reduction from baseline of ≥ 4 points in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score and
No new one or more British Isles Lupus Assessment Group (BILAG) A or new 2 or more BILAG B items compared to baseline using BILAG 2004 Index and
No worsening from baseline defined by an increase of &lt; 0.30 points from baseline on a Physician's Global Assessment (PGA) visual analog scale (VAS) from 0-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with SLEDAI 2K score improvement of ≥ 4 points from Baseline</measure>
    <time_frame>Weeks 24 and 52</time_frame>
    <description>The SLEDAI 2K score measures disease activity through assessment of 24 lupus manifestations using a weighted score of 1 to 8 points. A manifestation is recorded if it is present over the previous 30 days regardless of severity or whether it has improved or worsened. A SLEDAI 2K score of 3 to 4 points is representative of active disease and a decrease of 1 to 2 points is considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 50% reduction in Cutaneous Lupus Area and Severity Index (CLASI) activity score from baseline, in subjects with Baseline CLASI activity score ≥ 10</measure>
    <time_frame>Weeks 24 and 52</time_frame>
    <description>The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured
(1=yes; 0=no) and non-scarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with no new organ system affected as defined by 1 or more BILAG A or new 2 or more BILAG B items compared to Baseline using BILAG 2004 Index</measure>
    <time_frame>Weeks 24 and 52</time_frame>
    <description>The BILAG 2004 is a composite index that is based on the Classic BILAG index. It is a clinical measure of lupus disease activity. This tool assesses the changing severity of clinical manifestations of SLE using an ordinal scale scoring system that contain 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological). Activity in each organ system is scored as: A=most active disease; B=intermediate activity; C=mild, stable disease; D=previous involvement, currently inactive; E=no previous activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with no worsening (increase of &lt;0.30 points from Baseline) in Physician's Global Assessment (PGA) compared to Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in swollen joint count in subjects with ≥ 3 swollen joints at Baseline</measure>
    <time_frame>Week 24 and 52</time_frame>
    <description>Joint tenderness and swelling will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in tender joint count in subjects with ≥ 3 tender joints at Baseline</measure>
    <time_frame>Week 24 and 52</time_frame>
    <description>Joint tenderness will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in PGA score</measure>
    <time_frame>Week 24 and 52</time_frame>
    <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score</measure>
    <time_frame>Week 24 and 52</time_frame>
    <description>The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means &quot;not at all,&quot; and 4 means &quot;very much.&quot; The total FACIT-Fatigue score ranges from 0 to 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major clinical response defined as BILAG C or better in all organ domains at Week 24 with maintenance of this response through Week 52</measure>
    <time_frame>Week 24 and 52</time_frame>
    <description>The BILAG 2004 is a composite index that is based on the Classic BILAG index. It is a clinical measure of lupus disease activity. This tool assesses the changing severity of clinical manifestations of SLE using an ordinal scale scoring system that contain 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological). Activity in each organ system is scored as: A=most active disease; B=intermediate activity; C=mild, stable disease; D=previous involvement, currently inactive; E=no previous activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid Reduction- Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of subjects with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose average prednisone or equivalent dose has been reduced to ≤ 7.5 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24
The percentage of subjects with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose average prednisone or equivalent dose has been reduced to ≤ 10 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24
Percent change from Baseline in OCS dose in subjects with prednisone or equivalent ≥ 10 mg/day at Baseline.
AUC of the total corticosteroid dose from Baseline through Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid Reduction- Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The percentage of subjects with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose average prednisone or equivalent dose has been reduced to ≤ 7.5 mg/day by Week 40 and maintained through Week 52 with no flares between Week 40 and Week 52
The percentage of subjects with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose average prednisone or equivalent dose has been reduced to ≤ 10 mg/day by Week 40 and maintained through Week 52 with no flares between Week 40 and Week 52
Percent change from Baseline in OCS dose in subjects with prednisone or equivalent ≥ 10 mg/day at Baseline.
AUC of the total corticosteroid dose from Baseline through Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of SLE flare as defined by the SLE Flare Index</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The SLE Flare Index is defined by an increase in the SLEDAI of 3 or more points (mild or moderate flare) or a SLEDAI score greater than 12 (severe), a 0 to 3 visual analogue scale (VAS) with anchors for the physician global assessment (none, mild, moderate or severe flare) with an increase in 1 (for mild/moderate) or 2.5 (for severe) and adding NSAIDs or hydroxychloroquine (for mild) or steroids, but no more than 0.5 mg/kg/day and/or adding a new immunosuppressant (for severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing a SLE flare as defined by the SLE Flare Index</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The SLE Flare Index is defined by an increase in the SLEDAI of 3 or more points (mild or moderate flare) or a SLEDAI score greater than 12 (severe), a 0 to 3 visual analogue scale (VAS) with anchors for the physician global assessment (none, mild, moderate or severe flare) with an increase in 1 (for mild/moderate) or 2.5 (for severe) and adding NSAIDs or hydroxychloroquine (for mild) or steroids, but no more than 0.5 mg/kg/day and/or adding a new immunosuppressant (for severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>: Time to flare as defined by the SLE Flare Index</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The SLE Flare Index is defined by an increase in the SLEDAI of 3 or more points (mild or moderate flare) or a SLEDAI score greater than 12 (severe), a 0 to 3 visual analogue scale (VAS) with anchors for the physician global assessment (none, mild, moderate or severe flare) with an increase in 1 (for mild/moderate) or 2.5 (for severe) and adding NSAIDs or hydroxychloroquine (for mild) or steroids, but no more than 0.5 mg/kg/day and/or adding a new immunosuppressant (for severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index</measure>
    <time_frame>52 weeks</time_frame>
    <description>The SLICC/ACR Damage Index measures irreversible impairment since onset of SLE which has to be present for at least 6 months. Damage is defined for 12 separate organ systems: ocular (range 0-2), neuropsychiatric (0-6), renal (0-3), pulmonary (0-5), cardiovascular (0-6), peripheral vascular (0-5), gastrointestinal (0-6), musculoskeletal (0-7), skin (0-3), endocrine (diabetes) (0-1), gonadal (0-1) and malignancies (0-2). The maximum score for this assessment is 47 points.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>CC-220 0.45 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)
At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-220 0.3 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)
At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-220 0.15 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)
At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-220</intervention_name>
    <description>0.45 mg QD PO</description>
    <arm_group_label>CC-220 0.45 mg QD Placebo Controlled Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-220</intervention_name>
    <description>0.3 mg QD PO</description>
    <arm_group_label>C-220 0.3 mg QD Placebo Controlled Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-220</intervention_name>
    <description>0.15 mg QD PO</description>
    <arm_group_label>CC-220 0.15 mg QD Placebo Controlled Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo QD PO</description>
    <arm_group_label>CC-220 0.45 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>C-220 0.3 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>CC-220 0.15 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18 years of age or older at the time of signing the informed consent.

          2. Able and willing to adhere to the visit schedule and other protocol requirements.

          3. Have a diagnosis of SLE for at least 6 months prior to the Screening Visit and fulfill
             the 1997 update of the 1982 American College of Rheumatology (ACR) Classification
             Criteria for SLE at the Screening Visit.

          4. At the Screening Visit a Systemic Lupus Erythematosus Disease Activity Index (2K)
             (SLEDAI 2K) score of ≥ 6 points, at least four points of which are a &quot;clinical&quot; SLEDAI
             2K score. The &quot;clinical&quot; score is the SLEDAI 2K assessment score without the inclusion
             of points attributable to any urine or blood laboratory results including immunologic
             measures. Neurologic descriptors of the SLEDAI 2K are not counted towards the SLEDAI
             study entry criteria.

          5. At the Baseline Visit, a clinical SLEDAI 2K score of ≥ 4 points.

             Positive antibodies associated with SLE, which must include at least one of the
             following within the Screening Phase:

               -  Positive antinuclear antibody (ANA) test at the central laboratory with a titer
                  of 1:80 or greater, associated with a diagnosis of SLE, Anti-dsDNA antibodies
                  elevated to above normal as per the central laboratory,

               -  Anti-Smith (anti-Sm) antibody elevated to above normal as per the central
                  laboratory.

          6. Females of childbearing potential (FCBP) must:

               -  Have two negative pregnancy tests as verified by the investigator prior to
                  starting study therapy, one within 10 to 14 days prior to the first dose of
                  CC-220 and again within 24 hours before taking the first dose of CC-220. She must
                  agree to ongoing pregnancy testing during the course of the study, and after end
                  of study treatment. This applies even if the subject practices true abstinence
                  from heterosexual contact.

               -  Either commit to true abstinence2 from heterosexual contact (which must be
                  reviewed on a monthly basis and source documented) or agree to use two forms of
                  reliable contraception simultaneously. One must be a highly effective method and
                  one additional effective (barrier) method, and both must be practiced without
                  interruption, 28 days prior to starting investigational product, during the study
                  therapy (including dose interruptions), and for 28 days after discontinuation of
                  study therapy.

               -  Male subjects must: Practice true abstinence or agree to use a barrier
                  contraception (male latex condom or non-latex condom NOT made out of natural
                  [animal] membrane [for example, polyurethane]) during sexual contact with a
                  pregnant female or a female of childbearing potential while participating in the
                  study, during dose interruptions and for at least 90 days following
                  investigational product discontinuation, even if he has undergone a successful
                  vasectomy.

               -  Male subjects must agree not to donate semen or sperm during therapy and for at
                  least 90 days following the discontinuation of Investigational Product (IP).

          7. All subjects must:

               -  Understand that the IP could have potential teratogenic risk.

               -  Agree to abstain from donating blood while taking IP and for 28 days following
                  discontinuation of the IP.

               -  Agree not to share IP with another person.

               -  Other than the subject, FCBP and males able to father a child should not handle
                  the IP or touch the capsules unless gloves are worn.

               -  Be counseled about pregnancy precautions and risks of fetal exposure as described
                  in the Pregnancy Prevention Plan.

          8. If taking oral corticosteroids, must be on for at least 4 weeks prior to the Screening
             Visit, and maintained on a stable dose of ≤ 20 mg/d of prednisone or equivalent for at
             least 2 weeks prior to the Baseline Visit.

          9. If taking SLE standard of care treatment (e.g. anti-malarial, mycophenolate mofetil,
             azathioprine) for 12 weeks prior to and be on a stable dose for at least 4 weeks prior
             to Baseline.

        Exclusion Criteria:

          1. Must be off prohibited medications for a pre-specified period of time.

          2. Received intra-articular, intralesional, subcutaneous, intradermal, intramuscular or
             IV pulse corticosteroids 6 weeks prior to the Baseline Visit.

          3. Received an investigational product within 5 pharmacokinetic half-lives or one month,
             whichever is longer, prior to the Baseline Visit.

          4. Severe lupus nephritis defined as: estimated glomerular filtration rate (eGFR) of &lt; 45
             mL/1.73 m2 or proteinuria &gt; 2000 mg/day if stable for the past 3 months or proteinuria
             &gt; 500 mg/day if unstable.

          5. Proteinuria will be based upon spot urine testing.

          6. Active, severe or unstable neuropsychiatric lupus disease within 6 months of the
             Screening Visit.

          7. History or confirmed positive test for hepatitis B History of congenital and/or
             acquired mmunodeficiencies (eg, common variable immunodeficiency, human
             immunodeficiency virus [HIV], etc).

          8. Active or history of recurrent bacterial, viral, fungal, mycobacterial or other
             infections, or any major episode of infection requiring hospitalization or treatment
             with intravenous or oral antibiotics within 4 weeks of the Screening Visit and at any
             time during the Screening Phase, up through the first dose of IP.

          9. Active tuberculosis (TB) or a history of incompletely treated TB, or a positive,
             QuantiFERON®-TB Gold test.

         10. Malignancy or history of malignancy, except for:

               -  treated (eg, cured) basal cell or squamous cell in situ skin carcinomas

               -  treated (eg, cured) cervical intraepithelial neoplasia or carcinoma in situ of
                  the cervix with no evidence of recurrence within 5 years of the Screening Visit.

         11. Diagnosis of Antiphospholipid Syndrome History of arterial or venous thrombosis within
             one year of the Screening Visit.

         12. History or current diagnosis of peripheral neuropathy (sensory or motor) ≥ Grade 2.

         13. Presence of active uveitis or any other ophthalmological finding that in the opinion
             of the Investigator is clinically significant.

         14. Other non-SLE driven inflammatory joint or skin disease or overlap syndromes as the
             primary disease.

         15. Clinically significant or unstable or uncontrolled acute or chronic disease not due to
             SLE

         16. Does not meet required laboratory criteria.

         17. Pregnant or a breast-feeding female.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marla Hochfeld, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Rsch, PLLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Jude Heritage Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>C Michael Neuwelt M D</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology and Immunology Specialists</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bay Care Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jefrey Lieberman, MD, PC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033-5910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland - School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Associates of New Mexico</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011-4741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System-Division of Rheumatology</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanahan Rheumatology and Immunotherapy</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Systems</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-8807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Department of Dermatology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh UPMC Lupus Center of Excellence</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology &amp; Arthritis Research Center, PC</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Organización Médica de Investigación</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Jose Maria Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consultora Integral de Salud Centro Médico Privado</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CER Instituto Mèdico</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas de Quilmes</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Internacional de Pesquisas</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Terapias Inovadoras LTDA</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LMK Servicos Medicos S/S</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90480</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>State University of Campinas UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083-888</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre, RS</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Imunoterapia de Ipanema (CITIPA)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22411-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3Y1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MAC Research Incorporated</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto/Ontario</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUL du CHU de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique de Rhumatologie Du Centre Du Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPS Centro Integral de Reumatologia del Caribe Circaribe S.A.S.</name>
      <address>
        <city>Barranquilla</city>
        <zip>080002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S. - Cireem S.A.S</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Idearg S.A.S.</name>
      <address>
        <city>Bogota</city>
        <zip>111211</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicity S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Servimed S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preventive Care</name>
      <address>
        <city>Chia</city>
        <zip>250001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reumalab - Centro Integral de Reumatologia</name>
      <address>
        <city>Medellin</city>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille FR</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Pitie Salpetriere - AP HPService d'hematologie</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qualiclinic kft</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili P.O. di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Ferrara, Azienda Ospedaliera-Universitaria S.Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Cagliari</name>
      <address>
        <city>Monserrato</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biológicos Especializados S.A. de C.V.</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Integral de Osteoporosis y Artitis Reumatoide CLINOSAR</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación y Tratamiento Reumatológico</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral en Reumatología, S.A. de C.V.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatología e Investigación del Potosí S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis Potosí</state>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidad de Atencion Medica e Investigacion en Salud, S.C.</name>
      <address>
        <city>Merida</city>
        <state>Yucatán</state>
        <zip>97130</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles Lindavista</name>
      <address>
        <city>D.f, Df</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zespól Opieki Zdrowotnej w Koscianie Szpital im. Teodora Dunina</name>
      <address>
        <city>Koscian</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4, Klinika Reumatologii i Ukladowych Chorob Tkanki Laczne</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Biogenes Sp. z o.o.</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-224</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital</name>
      <address>
        <city>Kazan</city>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kemerovo State Medical Academy</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Medical Sciences Research Institute of Rheumatology of the Ru</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orenburg State Medical Academy</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioMed, LLC.</name>
      <address>
        <city>Vladimir</city>
        <zip>600005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Hopsital #1, Voronezh State Medical Academy</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute Niska Banja</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario a Coruna</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba - Txagorritxu</name>
      <address>
        <city>Vitoria-Gasteiz</city>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-220</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Active Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

